HR7879119th CongressWALLET

SUPER BUGS Act of 2026

Sponsored By: Representative Levin

Introduced

Summary

A coordinated international strategy to develop and commercialize pandemic medical products would direct the Secretary of State, working with HHS and other agencies, to build a global plan within 18 months to secure support for qualified pandemic or epidemic products, including tools against antimicrobial resistant pathogens.

Show full summary
  • Families and patients would see a focus on faster development and commercialization of vaccines, treatments, and diagnostics for pandemic threats and antibiotic resistant pathogens. The strategy would identify priority actions to steer scarce funds to the highest impact products.
  • Partner countries and global health systems would get support to strengthen detection, prevention, and containment. The plan would promote equitable contributions, harmonize efforts to avoid duplication, and set up arrangements with foreign governments and multilateral organizations.
  • U.S. companies and the private sector would be considered in contracts and public private partnerships. The strategy would explore alternative payment models, coverage and reimbursement pathways, and streamlined regulatory coordination to help commercialize qualifying products.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Global plan for pandemic products

If enacted, the bill would require the Secretary of State, with HHS and other agencies, to write a federal strategy within 18 months. The strategy would seek international support to develop and commercialize qualified pandemic or epidemic products, including products for antimicrobial-resistant and other priority pathogens. It would require processes for entering international arrangements, harmonizing new and existing efforts, strengthening partner-country public-health capacity, and identifying funding priorities. The strategy would have to consider contracts with U.S. companies, public-private partnerships, alternative payment and coverage approaches, faster regulatory pathways, and be submitted to four congressional committees.

Sponsors & CoSponsors

Sponsor

Levin

CA • D

Cosponsors

  • Valadao

    CA • R

    Sponsored 3/9/2026

  • Fitzpatrick

    PA • R

    Sponsored 3/19/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in